Lung Cancers and the Roles of Natural Compounds as Potential Chemotherapeutic and Chemopreventive Agents

Surien, Omchit; Ghazali, Ahmad Rohi; Masre, Siti Fathiah

doi:10.13005/bpj/1617

Cited by 10 publications

(9 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Small Cell Lung Carcinoma (SCLC) SCLC is a destructive type of cancer with increasing patient mortality risk. Over the past few decades, no appropriate treatment has been found effective against SCLC [41,77]. The survival and resistance of SCLC cells are mainly attributed to the overexpression of anti-apoptotic BCL-2 family members, such as BCL-XL and MCL-1.…”

Section: Pancreatic Ductal Adenocarcinoma (Pdac)mentioning

confidence: 99%

Combination Therapy of Navitoclax with Chemotherapeutic Agents in Solid Tumors and Blood Cancer: A Review of Current Evidence

et al. 2021

View full text Add to dashboard Cite

Combination therapy emerges as a fundamental scheme in cancer. Many targeted therapeutic agents are developed to be used with chemotherapy or radiation therapy to enhance drug efficacy and reduce toxicity effects. ABT-263, known as navitoclax, mimics the BH3-only proteins of the BCL-2 family and has a high affinity towards pro-survival BCL-2 family proteins (i.e., BCL-XL, BCL-2, BCL-W) to induce cell apoptosis effectively. A single navitoclax action potently ameliorates several tumor progressions, including blood and bone marrow cancer, as well as small cell lung carcinoma. Not only that, but navitoclax alone also therapeutically affects fibrotic disease. Nevertheless, outcomes from the clinical trial of a single navitoclax agent in patients with advanced and relapsed small cell lung cancer demonstrated a limited anti-cancer activity. This brings accumulating evidence of navitoclax to be used concomitantly with other chemotherapeutic agents in several solid and non-solid tumors that are therapeutically benefiting from navitoclax treatment in preclinical studies. Initially, we justify the anti-cancer role of navitoclax in combination therapy. Then, we evaluate the current evidence of navitoclax in combination with the chemotherapeutic agents comprehensively to indicate the primary regulator of this combination strategy in order to produce a therapeutic effect.

show abstract

Section: Pancreatic Ductal Adenocarcinoma (Pdac)mentioning

confidence: 99%

Combination Therapy of Navitoclax with Chemotherapeutic Agents in Solid Tumors and Blood Cancer: A Review of Current Evidence

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The SCC subtype is one of the primary malignancies of lung cancer, and it is characterized by late diagnosis and poor survival rate [ 33 , 34 , 35 ]. Thus, evaluating the underlying molecular mechanisms of lung SCC is crucial to understand the disease etiology.…”

Section: Discussionmentioning

confidence: 99%

Rigid Tissue Increases Cytoplasmic pYAP Expression in Pre-Malignant Stage of Lung Squamous Cell Carcinoma (SCC) In Vivo

Zakaria

Kiew

Rajab

et al. 2022

CIMB

View full text Add to dashboard Cite

Increased tissue rigidity is able to activate the Hippo signaling pathway, leading to YAP inactivation by phosphorylation and translocation into the cytoplasm. Accumulating evidence suggests that cytoplasmic pYAP serves as a tumor suppressor and could be a prognostic biomarker for several solid cancers. However, the relationship between tissue rigidity and cytoplasmic pYAP expression in the early stage of lung squamous cell carcinoma (SCC) remains elusive; this was determined in this study by using a mouse model. Female BALB/c mice were assigned into two groups (n = 6; the vehicle (VC) and the pre-malignant (PM) group, which received 70% acetone and 0.04 M N-nitroso-tris-chloroethylurea (NTCU) for 15 weeks, respectively. In this study, the formation of hyperplasia and metaplasia lesions was found in the PM group, indicating the pre-malignant stage of lung SCC. The pre-malignant tissue appeared to be more rigid as characterized by significantly higher (p < 0.05) epithelium thickness, proliferative activity, and collagen content than the VC group. The PM group also had a significantly higher (p < 0.05) cytoplasmic pYAP protein expression than the VC group. In conclusion, increased tissue rigidity may contribute to the upregulation of cytoplasmic pYAP expression, which may act as a tumor suppressor in the early stage of lung SCC.

show abstract

“…β-escin (a RhoA/ROCK inhibitor) for instance, has been evaluated to not cause significant body weight loss or histologic cytotoxicity on normal mice after 34 weeks of treatment, which indicates that this natural compound is unable to jeopardize general health (108). As reviewed by Surien et al (110), a number of natural compounds have been proven to be beneficial in the treatment of lung cancer at pre-clinical studies. From the literature search, the present review identified 6 different studies that evaluated ROCK expression following treatment with natural compounds (46,80,102,106-108).…”

Section: Rock Signaling Pathway Inhibition In Lung Cancermentioning

confidence: 99%

Roles of Rho‑associated kinase in lung cancer (Review)

et al. 2020

View full text Add to dashboard Cite

Lung cancer is one of the most lethal forms of cancer known to man, affecting millions of individuals worldwide. Despite advancements being made in lung cancer treatments, the prognosis of patients with the disease remains poor, particularly among patients with late-stage lung cancer. The elucidation of the signaling pathways involved in lung cancer is a critical approach for the treatment of the disease. Over the past decades, accumulating evidence has revealed that Rho-associated kinase (ROCK) is overexpressed in lung cancer and is associated with tumor growth. The present review discusses recent findings of ROCK signaling in the pathogenesis of lung cancer that were conducted in pre-clinical studies. The significant role of ROCK in cancer cell apoptosis, proliferation, migration, invasion and angiogenesis is discussed. The present review also suggests the use of ROCK as a potential target for the development of lung cancer therapies, as ROCK inhibition can reduce multiple hallmarks of cancer, particularly by decreasing cancer cell migration, which is an initial step of metastasis. Contents1. Introduction 2. Literature search 3. Overview of Rho-associated kinase signaling pathway 4. Roles of Rho/ROCK signaling pathway in modulating the behavior of lung cancer 5. ROCK signaling pathway inhibition in lung cancer 6. Other druggable targets of lung cancer 7. Conclusion and future direction

show abstract

Lung Cancers and the Roles of Natural Compounds as Potential Chemotherapeutic and Chemopreventive Agents

Cited by 10 publications

References 89 publications

Combination Therapy of Navitoclax with Chemotherapeutic Agents in Solid Tumors and Blood Cancer: A Review of Current Evidence

Combination Therapy of Navitoclax with Chemotherapeutic Agents in Solid Tumors and Blood Cancer: A Review of Current Evidence

Rigid Tissue Increases Cytoplasmic pYAP Expression in Pre-Malignant Stage of Lung Squamous Cell Carcinoma (SCC) In Vivo

Roles of Rho‑associated kinase in lung cancer (Review)

Contact Info

Product

Resources

About